Apalutamide Survival Benefits Unclear for Castration-Resistant Prostate Cancer
October 3rd 2019Despite prolonged progression-free duration, a 25% reduction in risk of death associated with anti-androgen agent apalutamide fell short of statistical significance in patients with non-metastatic, high-risk castration-resistant prostate cancer.
What Immunotherapy Combination Is Best in Metastatic Bladder Cancer?
November 15th 2018Extended follow-up from the CheckMate 032 trial showed strong results with three different immunotherapy regimens involving nivolumab and ipilimumab in patients with previously treated metastatic urothelial carcinoma.
Patient Perceptions on Importance of Chemo Side Effects Have Shifted
September 14th 2017The relative importance of common chemotherapy side effects has shifted substantially over the last few decades, according to a new study. In general, psychosocial effects have become more important while physical effects seem less significant to patients than in the past.
Adding Ramucirumab Prolongs PFS in Urothelial Carcinoma
September 13th 2017The combination of ramucirumab and docetaxel prolonged progression-free survival over chemotherapy alone in patients with platinum-refractory advanced urothelial carcinoma, the first time in this setting that a regimen has improved outcomes over chemotherapy.
Adjuvant Chemo Would Benefit Some Patients With Small Breast Tumors
September 13th 2017Nearly one quarter of breast cancer patients with small, node-negative tumors have high-risk genomic characteristics and would likely benefit from chemotherapy, according to results of a new study presented at the 2017 ESMO Congress.
Extended Results Confirm Pembrolizumab Superiority in Recurrent Urothelial Carcinoma
September 12th 2017The advantage with pembrolizumab has continued to improve, offering significantly better overall survival than chemotherapy in patients with recurrent, advanced urothelial carcinoma, according to the mature results of a phase III trial.
Combination of TKI, Anti-PD1 Agent Active in Metastatic RCC
September 12th 2017More than half of patients with metastatic clear cell renal cell carcinoma treated with a combination of lenvatinib and pembrolizumab responded to treatment at week 24, according to interim results of a phase I/II study presented at the 2017 ESMO Congress.
CT Surveillance After NSCLC Resection Does Not Improve Survival
September 12th 2017A study comparing two options for follow-up protocol after complete lung cancer resection suggests that regular CT scans after resection may not be necessary, though there may be some benefits to these additional scans.
Updated Results Show Continued Pembrolizumab Activity in Gastric Cancer
September 11th 2017Updated results from the KEYNOTE 059 phase II trial showed that pembrolizumab alone or in combination with chemotherapy has promising antitumor activity for patients with advanced gastric or gastroesophageal junction cancer.
Benefits Vary With Docetaxel and Abiraterone in High-Risk Prostate Cancer
September 11th 2017The first head-to-head comparison of docetaxel and abiraterone acetate for high-risk prostate cancer patients starting long-term hormone therapy found benefit with both treatments when added to ADT. Treatment decisions may come down to specific toxicities, which differ between the treatments.